However, the opposite result was obtained in one study: treatment of rIL-33 exacerbated Con A-induced hepatitis, but pretreatment with an IL-33-blocking antibody exhibited a protective effect, likely by suppressing the late stage of T cell and NKT cell activation and decreasing IFN-γ production [56]. This evidence concerns the gene IL33 and hepatitis A virus infection.